S. 1855 (112th): Pandemic and All-Hazards Preparedness Act Reauthorization of 2011

112th Congress, 2011–2013. Text as of Nov 10, 2011 (Introduced).

Status & Summary | PDF | Source: GPO

II

112th CONGRESS

1st Session

S. 1855

IN THE SENATE OF THE UNITED STATES

November 10, 2011

(for himself, Mr. Harkin, Mr. Enzi, Mr. Casey, Ms. Mikulski, Mr. Alexander, Mr. Lieberman, Ms. Collins, Mrs. Hagan, and Mr. Roberts) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the Public Health Service Act to reauthorize various programs under the Pandemic and All-Hazards Preparedness Act.

1.

Short title; table of contents

(a)

Short title

This Act may be cited as the Pandemic and All-Hazards Preparedness Act Reauthorization of 2011.

(b)

Table of contents

The table of contents of this Act is as follows:

Sec. 1. Short title; table of contents.

TITLE I—Strengthening national preparedness and response for public health emergencies

Sec. 101. National Health Security Strategy.

Sec. 102. Assistant Secretary for Preparedness and Response.

Sec. 103. Modernization of the National Disaster Medical System.

Sec. 104. Continuing the role of the Department of Veterans Affairs.

TITLE II—Optimizing State and local all-hazards preparedness and response

Sec. 201. Improving State and local public health security.

Sec. 202. Hospital preparedness and medical surge capacity.

Sec. 203. Enhancing situational awareness and biosurveillance.

TITLE III—Enhancing medical countermeasure review

Sec. 301. Special protocol assessment.

Sec. 302. Authorized use for medical products.

Sec. 303. Definitions.

Sec. 304. Enhancing medical countermeasure activities.

Sec. 305. Regulatory management plans.

Sec. 306. Report.

Sec. 307. Pediatric medical countermeasures.

Sec. 308. Technical and conforming amendments.

TITLE IV—Accelerating medical countermeasure advanced research and development

Sec. 401. BioShield.

Sec. 402. Biomedical Advanced Research and Development Authority.

Sec. 403. Strategic National Stockpile.

Sec. 404. National Biodefense Science Board.

I

Strengthening national preparedness and response for public health emergencies

101.

National Health Security Strategy

(a)

In general

Section 2802 of the Public Health Service Act (42 U.S.C. 300hh–1) is amended—

(1)

in subsection (a)(1), by striking 2009 and inserting 2014; and

(2)

in subsection (b)—

(A)

in paragraph (3)—

(i)

in the matter preceding subparagraph (A), by inserting and which may include dental health facilities after mental health facilities; and

(ii)

in subparagraph (D), by inserting (which may include such dental health assets) after medical assets;

(B)

in paragraph (4)—

(i)

in subparagraph (A), by inserting , including the unique needs and considerations of individuals with disabilities, after medical needs of at-risk individuals; and

(ii)

in subparagraph (B), by inserting the before purpose of this section; and

(C)

by adding at the end the following:

(7)

Countermeasures

(A)

Promoting strategic initiatives to advance countermeasures to diagnose, mitigate, prevent, or treat harm from any biological agent or toxin, chemical, radiological, or nuclear agent or agents.

(B)

For purposes of this paragraph the term countermeasures has the same meaning as the terms qualified countermeasures under section 319F–1, qualified pandemic and epidemic products under section 319F–3, and security countermeasures under section 319F–2.

(8)

Medical and public health community resiliency

Strengthening the ability of State and local communities to prepare for, respond to, and ensure resiliency in the event of public health emergencies, whether naturally occurring, unintentional, or deliberate by—

(A)

optimizing alignment and integration of medical and public health preparedness and response planning and capabilities with and into routine daily activities; and

(B)

promoting familiarity with local medical and public health systems.

.

(b)

At-Risk individuals

Section 2814 of the Public Health Service Act (42 U.S.C. 300hh–16) is amended—

(1)

by striking paragraph (7);

(2)

by redesignating paragraphs (1) through (6) and (8) as paragraphs (2) through (7) and (10), respectively;

(3)

by inserting before paragraph (2) (as so redesignated), the following:

(1)

monitor emerging issues and concerns as they relate to medical and public health preparedness and response for at-risk individuals in the event of a public health emergency declared by the Secretary under section 319;

; and

(4)

by inserting after paragraph (7) (as so redesignated), the following:

(8)

disseminate and, as appropriate, update novel and best practices of outreach to and care of at-risk individuals before, during, and following public health emergencies in as timely a manner as is practicable, including from the time a public health threat is identified;

(9)

ensure that public health and medical information distributed by the Department of Health and Human Services during a public health emergency is delivered in a manner that takes into account the range of communication needs of the intended recipients, including at-risk individuals; and

.

102.

Assistant Secretary for Preparedness and Response

Section 2811 of the Public Health Service Act (42 U.S.C. 300hh–10) is amended—

(1)

in subsection (b)(4), by adding at the end the following:

(D)

Policy coordination and strategic direction

Provide integrated policy coordination and strategic direction with respect to all matters related to Federal public health and medical preparedness and execution and deployment of the Federal response for public health emergencies and incidents covered by the National Response Plan developed pursuant to section 502(6) of the Homeland Security Act of 2002, or any successor plan, before, during, and following public health emergencies.

;

(2)

by striking subsection (c) and inserting the following:

(c)

Functions

The Assistant Secretary for Preparedness and Response shall—

(1)

have authority over and responsibility for—

(A)

the National Disaster Medical System (in accordance with section 301 of the Pandemic and All-Hazards Preparedness Act);

(B)

the Hospital Preparedness Cooperative Agreement Program pursuant to section 319C–2;

(C)

the Medical Reserve Corps pursuant to section 2813;

(D)

the Emergency System for Advance Registration of Volunteer Health Professionals pursuant to section 319I; and

(E)

administering grants and related authorities related to trauma care under parts A through C of title XII, such authority to be transferred by the Secretary from the Administrator of the Health Resources and Services Administration to such Assistant Secretary;

(2)

exercise the responsibilities and authorities of the Secretary with respect to the coordination of—

(A)

the Public Health Emergency Preparedness Cooperative Agreement Program pursuant to section 319C–1;

(B)

the Strategic National Stockpile; and

(C)

the Cities Readiness Initiative;

(3)

align and coordinate medical and public health preparedness and response grants and cooperative agreements authorized under this Act, to the extent possible, including program requirements, timelines, and measurable goals, and in coordination with the Secretary of Homeland Security, to—

(A)

optimize and streamline medical and public health preparedness capabilities and the ability of local communities to respond to public health emergencies;

(B)

minimize duplication of efforts with regard to medical and public health preparedness and response programs; and

(C)

gather and disseminate best practices among grant and cooperative agreement recipients, as appropriate;

(4)

carry out drills and operational exercises, in coordination with the Department of Homeland Security, the Department of Defense, and other applicable Federal departments and agencies, as necessary and appropriate, to identify, inform, and address gaps in and policies related to all-hazards medical and public health preparedness, including exercises based on—

(A)

identified threats for which countermeasures are available and for which no countermeasures are available; and

(B)

unknown threats for which no countermeasures are available; and

(5)

assume other duties as determined appropriate by the Secretary.

; and

(3)

by adding at the end the following:

(d)

National security priority

The Secretary, acting through the Assistant Secretary for Preparedness and Response, shall on a periodic basis conduct meetings, as applicable and appropriate, with the Assistant to the President for National Security Affairs to provide an update on, and discuss, medical and public health preparedness and response activities pursuant to this Act and the Federal Food, Drug, and Cosmetic Act, including progress on the development, approval, clearance, and licensure of medical countermeasures.

(e)

Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan

(1)

In general

Not later than 180 days after the date of enactment of this subsection, and every other year thereafter, the Secretary, acting through the Assistant Secretary for Preparedness and Response and in coordination with the Director of the Biomedical Advanced Research and Development Authority, the Director of the National Institutes of Health, the Director of the Centers for Disease Control and Prevention, and the Commissioner of the Food and Drug Administration, shall develop and submit to the appropriate committees of Congress a coordinated strategy and accompanying implementation plan for medical countermeasures to address chemical, biological, radiological, and nuclear threats. Such strategy and plan shall be known as the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan.

(2)

Requirements

The plan under paragraph (1) shall—

(A)

consider and reflect the full spectrum of medical countermeasure-related activities, including research, advanced research, development, procurement, stockpiling, deployment, and distribution;

(B)

identify and prioritize near-term, mid-term, and long-term priority qualified and security countermeasure (as defined in sections 319F–1 and 319F–2) needs and goals of the Federal Government according to chemical, biological, radiological, and nuclear threat or threats;

(C)

identify projected timelines, anticipated funding allocations, benchmarks, and milestones for each medical countermeasure priority under subparagraph (B), including projected needs with regard to replenishment of the Strategic National Stockpile;

(D)

be informed by the recommendations of the National Biodefense Science Board pursuant to section 319M;

(E)

report on advanced research and development awards and the date of the issuance of contract awards, including awards made through the special reserve fund (as defined in section 319F–2(c)(10));

(F)

identify progress made in meeting the goals, benchmarks, and milestones identified under subparagraph (C) in plans submitted subsequent to the initial plan; and

(G)

be made publically available.

(3)

GAO report

(A)

In general

Not later than 1 year after the date on which a Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan under this subsection is issued by the Secretary, the Government Accountability Office shall conduct an independent evaluation and submit to the appropriate committees of Congress a report concerning such strategy and implementation plan.

(B)

Content

The report described in subparagraph (A) shall review and assess—

(i)

the near-term, mid-term, and long-term medical countermeasure needs and identified priorities of the Federal Government pursuant to paragraph (2)(B);

(ii)

the activities of the Department of Health and Human Services with respect to advanced research and development pursuant to section 319L; and

(iii)

the progress made toward meeting the goals, benchmarks, and milestones identified in the Public Health Emergency Medical Countermeasures Enterprise Strategy and Implementation Plan under this subsection.

(f)

Internal multiyear planning process

The Secretary shall develop, and update on an annual basis, a coordinated 5-year budget plan based on the medical countermeasure priorities and goals described in subsection (e). Each such plan shall—

(1)

include consideration of the entire medical countermeasures enterprise, including—

(A)

basic research, advanced research and development;

(B)

approval, clearance, licensure, and authorized uses of products; and

(C)

procurement, stockpiling, maintenance, and replenishment of all products in the Strategic National Stockpile;

(2)

include measurable outputs and outcomes to allow for the tracking of the progress made toward identified goals;

(3)

identify medical countermeasure life-cycle costs to inform planning, budgeting, and anticipated needs within the continuum of the medical countermeasure enterprise consistent with section 319F–2; and

(4)

be made available to the appropriate committees of Congress upon request.

(g)

Interagency Coordination Plan

Not later than one year after the date of enactment of this subsection, the Secretary, in coordination with the Secretary of Defense, shall submit to the appropriate committees of Congress a report concerning the manner in which the Department of Health and Human Services is coordinating with the Department of Defense regarding countermeasure activities to address chemical, biological, radiological, and nuclear threats. Such report shall include information with respect to—

(1)

the research, advanced research, development, procurement, stockpiling, and distribution of countermeasures to meet identified needs; and

(2)

the coordination of efforts between the Department of Health and Human Services and the Department of Defense to address countermeasure needs for various segments of the population.

(h)

Protection of national security

In carrying out subsections (e), (f), and (g), the Secretary shall ensure that information and items that could compromise national security are not disclosed.

.

103.

Modernization of the National Disaster Medical System

Section 2812 of the Public Health Service Act (42 U.S.C. 300hh–11) is amended—

(1)

in subsection (a)(3), by adding at the end the following:

(A)

in subparagraph (A), in clause (i) by inserting , including at-risk individuals as applicable after victims of a public health emergency;

(B)

by redesignating subparagraph (C) as subparagraph (E); and

(C)

by inserting after subparagraph (B), the following:

(C)

Considerations for at-risk populations

The Secretary shall take steps to ensure that an appropriate specialized and focused range of public health and medical capabilities are represented in the National Disaster Medical System, which take into account the needs of at-risk individuals, in the event of a public health emergency.

.

(D)

Administration

The Secretary may determine and pay claims for reimbursement for services under subparagraph (A) directly or through contracts that provide for payment in advance or by way of reimbursement.

; and

(2)

in subsection (g), by striking such sums as may be necessary for each of the fiscal years 2007 through 2011 and inserting $56,000,000 for each of fiscal years 2012 through 2016.

104.

Continuing the role of the Department of Veterans Affairs

Section 8117(g) of title 38, United States Code, is amended by striking such sums as may be necessary to carry out this section for each of fiscal years 2007 through 2011 and inserting $156,500,000 for each of fiscal years 2012 through 2016 to carry out this section.

II

Optimizing State and local all-hazards preparedness and response

201.

Improving State and local public health security

(a)

Cooperative agreements

Section 319C–1 of the Public Health Service Act (42 U.S.C. 247d–3a) is amended—

(1)

in subsection (b)(2)—

(A)

in subparagraph (A)—

(i)

by striking clauses (i) and (ii) and inserting the following:

(i)

a description of the activities such entity will carry out under the agreement to meet the goals identified under section 2802, including with respect to chemical, biological, radiological, or nuclear threats;

(ii)

a description of the activities such entity will carry out with respect to pandemic influenza, as a component of the activities carried out under clause (i), and consistent with the requirements of paragraphs (2) and (5) of subsection (g);

;

(ii)

in clause (iv), by striking and at the end;

(iii)

in clause (v), by adding and after the semicolon; and

(iv)

by adding at the end the following:

(vi)

a description of how, as appropriate, the entity may partner with relevant public and private stakeholders in public health emergency preparedness and response

; and

(B)

in subparagraph (C), by inserting , including addressing the needs of at-risk individuals, after capabilities of such entity;

(2)

in subsection (g)—

(A)

in paragraph (1), by striking subparagraph (A) and inserting the following:

(A)

include outcome goals representing operational achievements of the National Preparedness Goals developed under section 2802(b) with respect to all-hazards, including chemical, biological, radiological, or nuclear threats

; and

(B)

in paragraph (2)(A), by adding at the end the following: The Secretary shall periodically update, as necessary and appropriate, such pandemic influenza plan criteria and shall require the integration of such criteria into the benchmarks and standards described in paragraph (1).; and

(3)

in subsection (i)—

(A)

in paragraph (1)(A)—

(i)

by striking $824,000,000 for fiscal year 2007 and inserting $632,900,000 for fiscal year 2012; and

(ii)

by striking such sums as may be necessary for each of fiscal years 2008 through 2011 and inserting $632,900,000 for each of fiscal years 2013 through 2016; and

(B)

by adding at the end the following:

(7)

Availability of cooperative agreement funds

(A)

In general

Amounts provided to an eligible entity under a cooperative agreement under subsection (a) for a fiscal year and remaining unobligated at the end of such year shall remain available to such entity for the next fiscal year for the purposes for which such funds were provided.

(B)

Funds contingent on achieving benchmarks

The continued availability of funds under subparagraph (A) with respect to an entity shall be contingent upon such entity achieving the benchmarks and submitting the pandemic influenza plan as described in subsection (g).

.

(b)

Vaccine tracking and distribution

Section 319A(e) of the Public Health Service Act (42 U.S.C. 247d–1(e)) is amended by striking such sums for each of fiscal years 2007 through 2011 and inserting $30,800,000 for each of fiscal years 2012 through 2016.

202.

Hospital preparedness and medical surge capacity

(a)

All-Hazards public health and medical response curricula and training

Section 319F(a)(5)(B) of the Public Health Service Act (42 U.S.C. 247d–6(a)(5)(B)) is amended by striking public health or medical and inserting public health, medical, or dental.

(b)

Encouraging health professional volunteers

(1)

Emergency system for advance registration of volunteer health professionals

Section 319I(k) of the Public Health Service Act (42 U.S.C. 247d–7b(k)) is amended by striking $2,000,000 for fiscal year 2002, and such sums as may be necessary for each of the fiscal years 2003 through 2011 and inserting $5,900,000 for each of fiscal years 2012 through 2016.

(2)

Volunteers

Section 2813 of the Public Health Service Act (42 U.S.C. 300hh–15) is amended—

(A)

in subsection (d)(2), by adding at the end the following: Such training exercises shall, as appropriate and applicable, incorporate the needs of at-risk individuals in the event of a public health emergency.; and

(B)

in subsection (i), by striking $22,000,000 for fiscal year 2007, and such sums as may be necessary for each of fiscal years 2008 through 2011 and inserting $11,900,000 for each of fiscal years 2012 through 2016.

(c)

Partnerships for State and regional preparedness To improve surge capacity

Section 319C–2 of the Public Health Service Act (42 U.S.C. 247d–3b) is amended—

(1)

by striking subsection (c) and inserting the following:

(c)

Use of funds

An award under subsection (a) shall be expended for activities to achieve the preparedness goals described under paragraphs (1), (3), (4), (5), and (6) of section 2802(b) with respect to all-hazards, including chemical, biological, radiological, or nuclear threats.

;

(2)

by striking subsection (g) and inserting the following:

(g)

Coordination

(1)

Local response capabilities

An eligible entity shall, to the extent practicable, ensure that activities carried out under an award under subsection (a) are coordinated with activities of relevant local Metropolitan Medical Response Systems, local Medical Reserve Corps, the local Cities Readiness Initiative, and local emergency plans.

(2)

National collaboration

Partnerships consisting of one or more eligible entities under this section may, to the extent practicable, collaborate with other partnerships consisting of one or more eligible entities under this section for purposes of national coordination and collaboration with respect to activities to achieve the preparedness goals described under paragraphs (1), (3), (4), (5), and (6) of section 2802(b).

; and

(3)

in subsection (j)—

(A)

in paragraph (1), by striking $474,000,000 for fiscal year 2007, and such sums as may be necessary for each of fiscal years 2008 through 2011 and inserting $378,000,000 for each of fiscal years 2012 through 2016; and

(B)

by adding at the end the following:

(4)

Availability of cooperative agreement funds

(A)

In general

Amounts provided to an eligible entity under a cooperative agreement under subsection (a) for a fiscal year and remaining unobligated at the end of such year shall remain available to such entity for the next fiscal year for the purposes for which such funds were provided.

(B)

Funds contingent on achieving benchmarks

The continued availability of funds under subparagraph (A) with respect to an entity shall be contingent upon such entity achieving the benchmarks and submitting the pandemic influenza plan as required under subsection (i).

.

203.

Enhancing situational awareness and biosurveillance

Section 319D of the Public Health Service Act (42 U.S.C. 247d–4) is amended—

(1)

in subsection (b)—

(A)

in paragraph (1)(B), by inserting poison control centers, after hospitals,;

(B)

in paragraph (2), by inserting before the period the following: , allowing for coordination to maximize all-hazards medical and public health preparedness and response and to minimize duplication of effort; and

(C)

in paragraph (3), by inserting before the period the following: and update such standards as necessary;

(2)

in subsection (d)—

(A)

in the subsection heading, by striking Public Health Situational Awareness and inserting Modernizing Public Health Situational Awareness and BioSurveillance;

(B)

in paragraph (1)—

(i)

by striking Pandemic and All-Hazards Preparedness Act and inserting Pandemic and All-Hazards Preparedness Act Reauthorization of 2011; and

(ii)

by inserting , novel emerging threats, after disease outbreaks;

(C)

by striking paragraph (2) and inserting the following:

(2)

Strategy and implementation plan

Not later than 180 days after the date of enactment of the Pandemic and All-Hazards Preparedness Act Reauthorization of 2011, the Secretary shall submit to the appropriate committees of Congress, a coordinated strategy and an accompanying implementation plan that identifies and demonstrates the measurable steps the Secretary will carry out to—

(A)

develop, implement, and evaluate the network described in paragraph (1), utilizing the elements described in paragraph (3); and

(B)

modernize and enhance biosurveillance activities.

;

(D)

in paragraph (5), by striking subparagraph (A) and inserting the following:

(A)

utilize applicable interoperability standards as determined by the Secretary, and in coordination with the Office of the National Coordinator for Health Information Technology, through a joint public and private sector process;

; and

(E)

by adding at the end the following:

(6)

Consultation with the National Biodefense Science Board

In carrying out this section consistent with section 319M, the National Biodefense Science Board shall provide expert advice and guidance, including recommendations, regarding the measurable steps the Secretary should take to modernize and enhance biosurveillance activities pursuant to the efforts of the Department of Health and Humans Services to ensure comprehensive, real-time all-hazards biosurveillance capabilities. In complying with the preceding sentence, the National Biodefense Science Board shall—

(A)

identify the steps necessary to achieve a national biosurveillance system for human health, with international connectivity, where appropriate, that is predicated on State, regional, and community level capabilities and creates a networked system to allow for two-way information flow between and among Federal, State, and local government public health authorities and clinical health care providers; and

(B)

identify any duplicative surveillance programs under the authority of the Secretary, or changes that are necessary to existing programs, in order to enhance and modernize such activities, minimize duplication, strengthen and streamline such activities under the authority of the Secretary, and achieve real-time and appropriate data that relate to disease activity, both human and zoonotic.

;

(3)

in subsection (e)(5), by striking 4 years after the date of enactment of the Pandemic and All-Hazards Preparedness Act, the Government Accountability Office and inserting 3 years after the date of enactment of the Pandemic and All-Hazards Preparedness Act Reauthorization of 2011;

(4)

in subsection (g), by striking such sums as may be necessary in each of fiscal years 2007 through 2011 and inserting $160,121,000 for each of fiscal years 2012 through 2016; and

(5)

by adding at the end the following:

(h)

Definition

For purposes of this section the term biosurveillance means the process of gathering near real-time, biological data that relates to disease activity and threats to human or zoonotic health, in order to achieve early warning of such health threats, early detection of health events, and overall situational awareness of disease activity.

.

III

Enhancing medical countermeasure review

301.

Special protocol assessment

Section 505(b)(5)(B) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)(5)(B)) is amended by striking size of clinical trials intended and all that follows through . The sponsor or applicant and inserting the following: “size—

(i)
(I)

of clinical trials intended to form the primary basis of an effectiveness claim; or

(II)

in the case where human efficacy studies are not ethical or practicable, of animal and clinical trials which, in combination, are intended to form the primary basis of an effectiveness claim; or

(ii)

with respect to an application for approval of a biological product under section 351(k) of the Public Health Service Act, of any necessary clinical study or studies.

The sponsor or applicant

.

302.

Authorized use for medical products

Section 564 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–3) is amended—

(1)

in the section heading, by striking for use in emergencies and inserting for use in response to declared emergency or identified material threat;

(2)

in subsection (a)—

(A)

in paragraph (1)—

(i)

in the paragraph heading, by striking Emergency and inserting Authorized; and

(ii)

by striking (referred to in this section as an emergency use) and inserting or with respect to a material threat (referred to in this section as an authorized use);

(B)

in paragraph (2), by striking an emergency use and inserting the use;

(C)

in paragraph (3), by striking An emergency use authorized and inserting An authorized use;

(D)

by redesignating paragraph (4) as paragraph (5);

(E)

by inserting after paragraph (3) the following:

(4)

Extension of expiration date

(A)

Authority to extend expiration date

The Secretary may extend the expiration date of an approved product in accordance with this paragraph.

(B)

Expiration date

For purposes of this paragraph, the term expiration date means the date that appears on the label of an approved product to reflect the results of stability testing and to ensure that the product meets applicable standards of identity, strength, quality, and purity at the time of use.

(C)

Effect of extension

If the expiration date of an approved product is extended by the Secretary under this paragraph, then, notwithstanding any other provision of this Act, the extended expiration date shall not affect the approval status of the product or the authorization of the product under this section.

(D)

Eligibility

A product shall be eligible for extension of the expiration date of such product if—

(i)
(I)

the product is intended for use to prevent, diagnose, or treat a disease or condition involving a biological, chemical, radiological, or nuclear agent or agents, including a product intended to be used to prevent or treat pandemic influenza; or

(II)

the product is intended for use to prevent, diagnose, or treat a serious or life-threatening disease or condition caused by a product described in subclause (I); and

(ii)

the product is intended for use during the circumstances of an emergency or a material threat described in subsection (b)(1).

(E)

Determinations by Secretary

Before extending the expiration date of an approved product under this paragraph, the Secretary shall determine—

(i)

that extension of the expiration date will help protect public health;

(ii)

that any extension of expiration is supported by scientific evaluation; and

(iii)

what changes to the product labeling, if any, are required or permitted, including whether and how any additional labeling communicating the extension of the expiration date may alter or obscure the labeling provided by the manufacturer.

(F)

Scope of extension

With respect to each extension of an expiration date granted under this paragraph, the Secretary shall determine—

(i)

the batch, lot, or unit to which such extension shall apply;

(ii)

the duration of such extension; and

(iii)

any conditions to effectuate such extension that are necessary and appropriate to protect public health or safety.

; and

(F)

in paragraph (5)(B), as so redesignated, by striking emergency use and inserting authorized use;

(3)

in subsection (b)—

(A)

in the subsection heading, by striking Emergency and inserting Emergency or Threat Justifying Authorized Use;

(B)

in paragraph (1)—

(i)

in the matter preceding subparagraph (A), by striking may declare an emergency and inserting may make a declaration that the circumstances exist;

(ii)

in subparagraph (B), by striking ; or and inserting a semicolon;

(iii)

in subparagraph (C), by striking national security and all that follows through the period and inserting national security, or the health and security of United States citizens living abroad, and that involves a specified biological, chemical, radiological, or nuclear agent or agents, or a specified disease or condition that may be attributable to such agent or agents; or; and

(iv)

by adding at the end the following:

(D)

the identification of a material threat pursuant to section 319F–2 of the Public Health Service Act sufficient to affect national security or the health and security of United States citizens living abroad.

;

(C)

in paragraph (2)(A)—

(i)

in clause (i), by striking ; or and inserting a semicolon;

(ii)

by redesignating clause (ii) as clause (iii); and

(iii)

by inserting after clause (i) the following:

(ii)

a change in the regulatory status of the product such that the circumstances described in subsection (a)(2) have ceased to exist; or

; and

(D)

in paragraph (3)(B), by striking emergency use and inserting authorized use;

(4)

in subsection (c)—

(A)

in the matter preceding paragraph (1)—

(i)

by striking emergency use and inserting authorized use;

(ii)

by inserting the Assistant Secretary for Preparedness and Response, after consultation with;

(iii)

by striking Health and and inserting Health, and; and

(iv)

by striking circumstances of the emergency involved and inserting applicable circumstances described in subsection (b)(1); and

(B)

in paragraph (2)—

(i)

in the matter preceding subparagraph (A), by inserting and the material threat posed by the agent or agents identified in a declaration under subsection (b)(1)(D), if applicable after if available,; and

(ii)

in subparagraph (B), by inserting taking into consideration the material threat posed by the agent or agents identified in a declaration under subsection (b)(1)(D), if applicable after risks of the product,;

(5)

in subsection (e)(1)—

(A)

in subparagraph (A), in the matter preceding clause (i)—

(i)

by striking emergency use and inserting authorized use; and

(ii)

by striking circumstances of the emergency and inserting applicable circumstances described in subsection (b)(1);

(B)

in subparagraph (A)(i)—

(i)

in subclause (I), by striking has authorized the emergency use and inserting has authorized under this section the use; and

(ii)

in subclause (II), by striking emergency use and inserting authorized use;

(C)

in subparagraph (A)(ii)(I), by striking authorized the emergency use and inserting has authorized under this section the use;

(D)

in clauses (iii) and (iv) of subparagraph (A), by striking emergency use each place such term appears and inserting authorized use;

(E)

in subparagraph (A), by adding at the end the following:

(v)

Appropriate conditions with respect to the collection and analysis of safety and effectiveness information useful to inform the approval, licensure, or clearance of the product, especially for a product for which human efficacy studies are not ethical or practicable.

;

(F)

in subparagraph (B)—

(i)

by striking emergency use each place such term appears and inserting authorized use;

(ii)

by striking clause (iii); and

(iii)

by redesignating clause (iv) as clause (iii);

(6)

in subsection (e)—

(A)

in paragraph (2)—

(i)

by striking emergency use each place such term appears and inserting authorized use; and

(ii)

in subparagraph (A), by striking circumstances of the emergency and inserting applicable circumstances described in subsection (b)(1);

(B)

in paragraph (3)—

(i)

by striking emergency use and inserting use; and

(ii)

by striking circumstances of the emergency and inserting applicable circumstances described in subsection (b)(1); and

(C)

in paragraph (4), by striking emergency use and inserting use;

(7)

in subsection (g)—

(A)

in the subsection heading, by inserting Review and before Revocation;

(B)

in paragraph (1), by inserting after the period at the end the following: “As part of such review, the Secretary shall regularly review the progress made with respect to the approval, licensure, or clearance of—

(A)

an unapproved product for which an authorization was issued under this section; or

(B)

an unapproved use of an approved product for which an authorization was issued under this section.

; and

(C)

by amending paragraph (2) to read as follows:

(2)

Revision and revocation

The Secretary may revise or revoke an authorization under this section if—

(A)

the circumstances described under subsection (b)(1) no longer exist;

(B)

the criteria under subsection (c) for issuance of such authorization are no longer met; or

(C)

other circumstances make such revision or revocation appropriate to protect the public health or safety.

; and

(8)

in subsection (h)(1), by inserting , revision, after termination.

303.

Definitions

Section 565 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4) is amended by striking The Secretary, in consultation and inserting the following:

(a)

Definitions

In this section—

(1)

the term countermeasure means a qualified countermeasure, a security countermeasure, and a qualified pandemic or epidemic product;

(2)

the term qualified countermeasure has the meaning given such term in section 319F–1 of the Public Health Service Act;

(3)

the term qualified pandemic or epidemic product has the meaning given such term in section 319F–3 of such Act; and

(4)

the term security countermeasure has the meaning given such term in section 319F–2 of such Act.

(b)

General duties

The Secretary, in consultation

.

304.

Enhancing medical countermeasure activities

Section 565 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4), as amended by section 303, is further amended—

(1)

in the section heading, by striking Technical Assistance and inserting Countermeasure Development, Review, and Technical Assistance;

(2)

in subsection (b), by striking the subsection heading and all that follows through shall establish and inserting the following:

(b)

General duties

The Secretary, in consultation with the Assistant Secretary for Preparedness and Response, shall accelerate the development, stockpiling, approval, licensure, and clearance of qualified countermeasures, security countermeasures, and qualified pandemic or epidemic products—

(1)

by ensuring the appropriate involvement of Food and Drug Administration personnel in interagency activities related to countermeasure advanced research and development, consistent with sections 319F, 319F–1, 319F–2, 319F–3, and 319L of the Public Health Service Act;

(2)

by ensuring the appropriate involvement and consultation of Food and Drug Administration personnel in any flexible manufacturing activities carried out under section 319L of the Public Health Service Act, including with respect to meeting regulatory requirements set forth in this Act;

(3)

by promoting countermeasure expertise within the Food and Drug Administration by—

(A)

ensuring that Food and Drug Administration personnel involved in reviewing countermeasures for approval, licensure, or clearance are informed by the Assistant Secretary for Preparedness and Response on the material threat assessment conducted under section 319F–2 of the Public Health Service Act for the agent or agents for which the countermeasure under review is intended;

(B)

training Food and Drug Administration personnel regarding review of countermeasures for approval, licensure, or clearance; and

(C)

establishing protocols to ensure that countermeasure reviewers have sufficient training or experience with countermeasures;

(4)

by maintaining teams, composed of Food and Drug Administration personnel with expertise on countermeasures (including specific countermeasures, classes or groups of countermeasures, or other countermeasure-related technologies and capabilities), that shall—

(A)

work with countermeasure sponsors and applicants to identify and help resolve scientific issues related to the approval, licensure, or clearance of countermeasures;

(B)

encourage the exchange of scientific ideas by holding public meetings at least twice annually; and

(C)

improve and advance the science relating to the development of new tools, standards, and approaches to assessing and evaluating countermeasures—

(i)

in order to inform the process for countermeasure approval, clearance, and licensure; and

(ii)

with respect to the development of countermeasures for populations with special clinical needs, including children and pregnant women, in order to meet the needs of such populations, as necessary and appropriate; and

(5)

by establishing

; and

(3)

by adding at the end the following:

(c)

Development and animal modeling procedures

(1)

Availability of animal model meetings

To facilitate the timely development of animal models and support the development, stockpiling, licensure, approval, and clearance of countermeasures, the Secretary shall, not later than 180 days after the enactment of this subsection, establish a procedure by which a sponsor or applicant that is developing a countermeasure for which human efficacy studies are not ethical or practicable, and that has an approved investigational new drug application or investigational device exemption, may request and receive—

(A)

a meeting to discuss proposed animal model development activities; and

(B)

a meeting prior to initiating pivotal animal studies.

(2)

Juvenile models

To facilitate the development and selection of animal models that could translate to juvenile studies, any meeting conducted under paragraph (1) shall include discussion of juvenile animal models, as appropriate.

(d)

Review and approval of countermeasures

(1)

Material threat

When evaluating an application or submission for approval, licensure, or clearance of a countermeasure, the Secretary shall take into account the material threat posed by the chemical, biological, radiological, or nuclear agent or agents identified under section 319F–2 of the Public Health Service Act for which the countermeasure under review is intended.

(2)

Review expertise

When practicable and appropriate, teams of Food and Drug Administration personnel reviewing applications or submissions described under paragraph (1) shall include a reviewer with sufficient training or experience with countermeasures pursuant to the protocols established under subsection (b)(3)(C).

.

305.

Regulatory management plans

Section 565 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4), as amended by section 304, is further amended by adding at the end the following:

(e)

Regulatory management plan

(1)

In general

(A)

Initiation of process

The Secretary, in consultation with the Assistant Secretary for Preparedness and Response and the product sponsor or applicant, shall initiate a formal process for obtaining scientific feedback and interactions regarding the development and regulatory review of any countermeasure.

(B)

Content

(i)

In general

The process initiated under subparagraph (A) shall include the development of a written regulatory management plan that shall be made part of the administrative record. Except as provided in paragraph (2), such plan shall be completed not later than 45 days after the date on which an investigational new drug application or investigational device exemption is approved with respect to the countermeasure involved.

(ii)

Content of plan

The content of a regulatory management plan under clause (i) shall be consistent with sections 319L and 319F–2 of the Public Health Service Act. Such plan shall include—

(I)

guidance from the Secretary regarding the data required to support the approval, clearance, or licensure of the countermeasure involved;

(II)

guidance from the Secretary regarding the data necessary to inform any authorization under section 564;

(III)

guidance from the Secretary regarding the data necessary to support the positioning and delivery of countermeasures, including to the Strategic National Stockpile;

(IV)

guidance from the Secretary regarding the data necessary to support the submission of protocols for review under section 505(b)(5)(B);

(V)

an agreement between the Secretary and the countermeasure sponsor or applicant regarding developmental milestones that will trigger responses by the Secretary as described in subclause (VI);

(VI)

performance targets and goals for timely and appropriate responses by the Secretary to the triggers described under subclause (V), including meetings between the Secretary and the sponsor or applicant, written feedback, decisions by the Secretary, and other activities carried out as part of the development and review process;

(VII)

guidance from the Secretary regarding any gaps in scientific knowledge that will need resolution prior to countermeasure approval, licensure, or clearance, and plans for conducting the necessary scientific research;

(VIII)

identification of the population for which the countermeasure sponsor or applicant seeks approval, licensure, or clearance, and the population for which desired labeling would not be appropriate, if known; and

(IX)

as necessary and appropriate, and to the extent practicable, a plan for developing pediatric dosing and administration with respect to the countermeasure.

(iii)

Modification of plan

Not later than 45 days after the Secretary becomes aware of a new substantial scientific issue essential to the review of a countermeasure, the Secretary shall—

(I)

determine, in consultation with the countermeasure sponsor or applicant, if such issue necessitates a modification to the regulatory management plan; and

(II)

if the Secretary so determines, make such modification.

(2)

Countermeasures under review

(A)

In general

Not later than 45 days after the date of enactment of this subsection, the Secretary shall establish a procedure for developing regulatory management plans for countermeasures that are under review by the Food and Drug Administration as of the date of enactment of this subsection. Subject to subparagraph (B), the regulatory management plans for all such countermeasures shall be developed not later than 274 days after the date of enactment of this subsection.

(B)

Exception

The sponsor or applicant with respect to a countermeasure described subparagraph (A) may elect not to establish a regulatory management plan under this subsection. Such sponsor or applicant shall notify the Secretary of such an election not later than 30 days after the Secretary makes the procedures established under subparagraph (A) publicly available. If notification of such an election is not received by the Secretary by such date, the procedures established under subparagraph (A) shall apply to the countermeasure.

.

306.

Report

Section 565 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4), as amended by section 305, is further amended by adding at the end the following:

(f)

Annual report

Not later than 180 days after the date of enactment of this subsection, and annually thereafter, the Secretary shall submit to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives a report that details the countermeasure development and review activities of the Food and Drug Administration, including—

(1)

with respect to the development of new tools, standards, and approaches to assess and evaluate countermeasures—

(A)

the identification of the priorities of the Food and Drug Administration and the progress made on such priorities; and

(B)

the identification of scientific gaps that impede the development or approval, licensure, or clearance of countermeasures for populations with special clinical needs, including children and pregnant women, and the progress made on resolving these challenges;

(2)

the extent to which the performance targets and goals set forth in subsection (e)(1)(B) and the regulatory management plans established under such subsection have been met, including, for each countermeasure reviewed—

(A)

whether the regulatory management plan was completed within the required timeframe, and the length of time taken to complete such plan;

(B)

whether the Secretary adhered to the timely and appropriate response times set forth in such plan; and

(C)

explanations for any failure to meet such performance targets and goals;

(3)

the number of regulatory teams established pursuant to subsection (b)(4) and the number of products, classes of products, or technologies assigned to each such team;

(4)

an estimate of resources obligated to countermeasure development and regulatory assessment, including Center specific objectives and accomplishments; and

(5)

the number of countermeasure applications submitted, the number of countermeasures approved, licensed, or cleared, the status of remaining submitted applications, and the number of each type of authorization issued pursuant to section 564.

.

307.

Pediatric medical countermeasures

(a)

Pediatric studies of drugs

Section 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a) is amended—

(1)

in subsection (d), by adding at the end the following:

(5)

Consultation

With respect to a drug that is a qualified countermeasure (as defined in section 319F–1 of the Public Health Service Act), a security countermeasure (as defined in section 319F–2 of the Public Health Service Act), or a qualified pandemic or epidemic product (as defined in section 319F–3 of the Public Health Service Act), the Secretary shall solicit input from the Assistant Secretary for Preparedness and Response regarding the need for and conduct of pediatric studies under this section.

; and

(2)

in subsection (n)(1), by adding at the end the following:

(C)

For a drug that is a qualified countermeasure (as defined in section 319F–1 of the Public Health Service Act), a security countermeasure (as defined in section 319F–2 of the Public Health Service Act), or a qualified pandemic or epidemic product (as defined in section 319F–3 of such Act), prior to any action with respect to such drug under subparagraph (A) or (B), the Secretary shall refer all pediatric studies in the written request to the Assistant Secretary for Preparedness and Response and the Director of the Biomedical Advanced Research and Development Authority.

.

(b)

Addition to priority list considerations

Section 409I of the Public Health Service Act (42 U.S.C. 284m) is amended—

(1)

by striking subsection (a)(2) and inserting the following:

(2)

Consideration of available information

In developing and prioritizing the list under paragraph (1), the Secretary—

(A)

shall consider—

(i)

therapeutic gaps in pediatrics that may include developmental pharmacology, pharmacogenetic determinants of drug response, metabolism of drugs and biologics in children, and pediatric clinical trials;

(ii)

particular pediatric diseases, disorders or conditions where more complete knowledge and testing of therapeutics, including drugs and biologics, may be beneficial in pediatric populations; and

(iii)

the adequacy of necessary infrastructure to conduct pediatric pharmacological research, including research networks and trained pediatric investigators; and

(B)

may consider the availability of qualified countermeasures (as defined in section 319F–1), security countermeasures (as defined in section 319F–2), and qualified pandemic or epidemic products (as defined in section 319F–3) to address the needs of pediatric populations, in consultation with the Assistant Secretary for Preparedness and Response, consistent with the purposes of this section.

; and

(2)

in subsection (b), by striking subsection (a) and inserting paragraphs (1) and (2)(A) of subsection (a).

(c)

Advice and recommendations of the pediatric advisory committee regarding countermeasures for pediatric populations

Subsection (b)(2) of section 14 of the Best Pharmaceuticals for Children Act (42 U.S.C. 284m note) is amended—

(1)

in subparagraph (C), by striking the period and inserting ; and; and

(2)

by adding at the end the following:

(D)

the development of countermeasures (as defined in section 565(a) of the Federal Food, Drug, and Cosmetic Act) for pediatric populations.

.

308.

Technical and conforming amendments

(a)

Section 319F–2(c)(1)(B)(ii) of the Public Health Service Act (42 U.S.C. 247d–6b(c)(1)(B)(ii)) is amended by striking emergency.

(b)

Section 319F–3(i) of such Act (42 U.S.C. 247d–6d(i)) is amended—

(1)

in paragraph (1)(C), by striking emergency; and

(2)

in paragraph (7)(B)(iii), by striking emergency.

IV

Accelerating medical countermeasure advanced research and development

401.

BioShield

(a)

Reauthorization of the special reserve fund

Section 319F–2(c) of the Public Health Service Act (42 U.S.C. 247d-6b(c)) is amended by adding at the end the following:

(11)

Reauthorization of the special reserve fund

In addition to amounts otherwise appropriated, there are authorized to be appropriated for the special reserve fund, $2,800,000,000 for the fiscal years 2014 through 2018.

(12)

Report

Not later than 30 days after any date on which the Secretary determines that the amount of funds in the special reserve fund available for procurement is less than $1,500,000,000, the Secretary shall submit to the appropriate committees of Congress a report detailing the amount of such funds available for procurement and the impact such reduction in funding will have—

(A)

in meeting the security countermeasure needs identified under this section; and

(B)

on the annual Public Health Emergency Medical Countermeasures Enterprise and Strategy Implementation Plan (pursuant to section 2811(d)).

.

(b)

Procurement of countermeasures

Section 319F–2(c) of the Public Health Service Act (42 U.S.C. 247d–6b(c)) is amended—

(1)

in paragraph (1)(B)(i)(III)(bb), by striking eight years and inserting 10 years;

(2)

in paragraph (5)(B)(ii), by striking eight years and inserting 10 years;

(3)

in paragraph (7)(C)—

(A)

in clause (i)(I), by inserting including advanced research and development, after as may reasonably be required,;

(B)

in clause (ii)—

(i)

in subclause (III), by striking eight years and inserting 10 years; and

(ii)

by striking subclause (IX) and inserting the following:

(IX)

Contract terms

The Secretary, in any contract for procurement under this section—

(aa)

may specify—

(AA)

the dosing and administration requirements for the countermeasure to be developed and procured;

(BB)

the amount of funding that will be dedicated by the Secretary for advanced research, development, and procurement of the countermeasure; and

(CC)

the specifications the countermeasure must meet to qualify for procurement under a contract under this section; and

(bb)

shall provide a clear statement of defined Government purpose limited to uses related to a security countermeasure, as defined in paragraph (1)(B).

; and

(C)

by adding at the end the following:

(viii)

Flexibility

In carrying out this section, the Secretary may, consistent with the applicable provisions of this section, enter into contracts and other agreements that are in the best interest of the Government in meeting identified security countermeasure needs, including with respect to reimbursement of the cost of advanced research and development as an allowable and allocable direct cost of the contract involved.

;

(4)

in paragraph (9)(B), by inserting before the period the following: , except that this subparagraph shall not be construed to prohibit the use of such amounts as otherwise authorized in this title; and

(5)

in paragraph (10), by adding at the end the following:

(C)

Advanced research and development

For purposes of this paragraph, the term advanced research and development shall have the meaning given such term in section 319L(a).

.

402.

Biomedical Advanced Research and Development Authority

(a)

Duties

Section 319L(c)(4) of the Public Health Service Act (42 U.S.C. 247d–7e(c)(4)) is amended—

(1)

in subparagraph (B)(iii), by inserting (which may include advanced research and development for purposes of fulfilling requirements under the Federal Food, Drug, and Cosmetic Act or section 351 of this Act) after development; and

(2)

in subparagraph (D)(iii), by striking and vaccine manufacturing technologies and inserting vaccine manufacturing technologies, dose sparing technologies, efficacy increasing technologies, and platform technologies.

(b)

Transaction authorities

Section 319L(c)(5) of the Public Health Service Act (42 U.S.C. 247d–7e(c)(5)) is amended by adding at the end the following:

(G)

Government purpose

In awarding contracts, grants, and cooperative agreements under this section, the Secretary shall provide a clear statement of defined Government purpose related to activities included in subsection (a)(6)(B) for a qualified countermeasure or qualified pandemic or epidemic product.

.

(c)

Fund

Paragraph (2) of section 319L(d) of the Public Health Service Act (42 U.S.C. 247d–7e(d)(2)) is amended to read as follows:

(2)

Funding

To carry out the purposes of this section, there is authorized to be appropriated to the Fund $415,000,000 for each of fiscal years 2012 through 2016, such amounts to remain available until expended.

.

(d)

Continued Inapplicability of Certain Provisions

Section 319L(e)(1)(C) of the Public Health Service Act (42 U.S.C. 247d–7e(e)(1)(C)) is amended by striking 7 years and inserting 10 years.

(e)

Extension of limited antitrust exemption

Section 405(b) of the Pandemic and All-Hazards Preparedness Act (42 U.S.C. 247d–6a note) is amended by striking 6-year and inserting 10-year.

(f)

Independent evaluation

Section 319L of the Public Health Service Act (42 U.S.C. 247d–7e) is amended by adding at the end the following:

(f)

Independent evaluation

(1)

In general

Not later than 180 days after the date of enactment of this subsection, the Government Accountability Office shall conduct an independent evaluation of the activities carried out to facilitate flexible manufacturing capacity pursuant to this section.

(2)

Report

Not later than 1 year after the date of enactment of this subsection, the Government Accountability Office shall submit to the appropriate committees of Congress a report concerning the results of the evaluation conducted under paragraph (1). Such report shall review and assess—

(A)

the extent to which flexible manufacturing capacity under this section is dedicated to chemical, biological, radiological, and nuclear threats;

(B)

the activities supported by flexible manufacturing initiatives; and

(C)

the ability of flexible manufacturing activities carried out under this section to—

(i)

secure and leverage leading technical expertise with respect to countermeasure advanced research, development, and manufacturing processes; and

(ii)

meet the surge manufacturing capacity needs presented by novel and emerging threats, including chemical, biological, radiological and nuclear agents.

.

(g)

Definitions

(1)

Qualified countermeasure

Section 319F–1(a)(2)(A) of the Public Health Service Act (42 U.S.C. 247d–6a(a)(2)(A)) is amended—

(A)

in the matter preceding clause (i), by striking to— and inserting ;

(B)

in clause (i)—

(i)

by striking diagnose and inserting to diagnose; and

(ii)

by striking ; or and inserting a semicolon;

(C)

in clause (ii)—

(i)

by striking diagnose and inserting to diagnose; and

(ii)

by striking the period at the end and inserting ; or; and

(D)

by adding at the end the following:

(iii)

is a product or technology intended to enhance the purpose of a drug, biological product, or device described in clause (i) or (ii).

.

(2)

Qualified pandemic or epidemic product

Section 319F–3(i)(7)(A) of the Public Health Service Act (42 U.S.C. 247d–6d(i)(7)(A)) is amended—

(A)

in clause (i)(II), by striking ; or and inserting ;;

(B)

in clause (ii), by striking ; and and inserting ; or; and

(C)

by adding at the end the following:

(B)

a product or technology intended to enhance the purpose of a drug, biological product, or device described in clause (i) or (ii); and

.

403.

Strategic National Stockpile

Section 319F–2 of the Public Health Service Act (42 U.S.C. 247d–6b) is amended—

(1)

in subsection (a)—

(A)

in paragraph (1)—

(i)

by inserting consistent with section 2811 before by the Secretary to be appropriate; and

(ii)

by inserting before the period at the end the following: and shall submit such review annually to the appropriate Congressional committees of jurisdiction to the extent that disclosure of such information does not compromise national security; and

(B)

in paragraph (2)—

(i)

by redesignating subparagraphs (E) through (H) as subparagraphs (F) through (I), respectively; and

(ii)

by inserting after subparagraph (D), the following:

(E)

identify and address the potential depletion and ensure appropriate replenishment of medical countermeasures, including those currently in the stockpile;

; and

(2)

in subsection (f)(1), by striking $640,000,000 for fiscal year 2002, and such sums as may be necessary for each of fiscal years 2003 through 2006 and inserting $522,486,000 for each of fiscal years 2012 through 2016.

404.

National Biodefense Science Board

Section 319M(a) of the Public Health Service Act (42 U.S.C. 247d–f(a)) is amended—

(1)

in paragraph (2)—

(A)

in subparagraph (D)—

(i)

in the matter preceding clause (i), by striking five and inserting six;

(ii)

in clause (i), by striking and at the end;

(iii)

in clause (ii), by striking the period and inserting a semicolon; and

(iv)

by adding at the end the following:

(iii)

one such member shall be an individual with pediatric subject matter expertise; and

(iv)

one such member shall be a State, tribal, territorial, or local public health official.

; and

(B)

by adding at the end the following flush sentence:

Nothing in this paragraph shall preclude a member of the Board from satisfying two or more of the requirements described in subparagraph (D).;
(2)

in paragraph (5)—

(A)

in subparagraph (B), by striking and at the end;

(B)

in subparagraph (C), by striking the period and inserting ; and; and

(C)

by adding at the end the following:

(D)

provide any recommendation, finding, or report provided to the Secretary under this paragraph to the appropriate committees of Congress.

; and

(3)

in paragraph (8), by adding at the end the following: Such chairperson shall serve as the deciding vote in the event that a deciding vote is necessary with respect to voting by members of the Board..